Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative biologic medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 130 drug products in clinical development and the manufacture of eight commercial products.
As part of a comprehensive drug development process, the Company’s technologies – offered under flexible, customized contractual agreements – shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
As part of a comprehensive drug development process, the Company’s technologies – offered under flexible, customized contractual agreements – shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Location: Switzerland, Geneva, Arare
Employees: 51-200
Phone: +41 22 308 93 60
Founded date: 2001
Investors 1
| Date | Name | Website |
| - | Fongit See... | fongitseed... |
Mentions in press and media 18
| Date | Title | Description |
| 13.11.2024 | Cell Line Development Market to Surpass Market Valuation of USD 15.88 Billion by 2031 | SkyQuest Technology | Westford, USA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Global Cell Line Development Market will reach a value of USD 15.88 Billion by 2031, with a CAGR of 12.12% during the forecast period (2024-2031). Cell line develop... |
| 20.10.2020 | New management at life sciences start-ups | Aktiia SA is a Swiss-US start-up developing an accurate, wrist-worn optical blood pressure monitor that can automatically take measurements 24/7. As the company rapidly approaches the commercial launch of its product, Aktiia welcomed Michae... |
| 20.10.2020 | New management at life sciences start-ups | |
| 17.10.2019 | After 13% discount Innate Pharma raises $69M; AZTherapies bags $26.3M from Series C financing round | → AstraZeneca-partnered French biotech Innate Pharma — which was shooting for a $100 million IPO by offering 10.7 millions shares at $7.50 per share last month — has raised $69 million in the US by offering 12.5 million shares ... |
| 16.04.2018 | Selexis invests in Geneva | |
| 29.11.2017 | Venture Kick: 5000 new jobs in 10 years | |
| 27.06.2017 | Mitoconix lands $20M to develop neurodegenerative platform out of Stanford; RaNA gets a new name following mRNA deal with Shire | → Mitoconix has a neurodegeneration platform tech from Stanford and a base in Israel from which it plans to push its lead therapy into clinical testing with the help of a $20 million A round. The science comes from the lab... |
| 21.02.2017 | Selexis Inks Agreement with Sanofi | |
| 09.01.2015 | First Selexis SUREtechnology Generated Antibody Approved for Market | |
| 25.06.2014 | Developing a biosimilar in nine months |
Show more